Kenneth Harry Persen - May 14, 2023 Form 4 Insider Report for HeartBeam, Inc. (BEAT)

Role
Chief Technology Officer
Signature
/s/ Kenneth Persen
Stock symbol
BEAT
Transactions as of
May 14, 2023
Transactions value $
$0
Form type
4
Date filed
6/9/2023, 07:59 PM
Previous filing
Mar 23, 2023
Next filing
Aug 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAT Stock option (right to buy) Award $0 +169K $0.00 169K May 14, 2023 Common Stock 169K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price per share of each option (?Option? and collectively, the ?Options?) shall be the Fair Market Value (as defined in the Company?s 2022 Equity Incentive Plan) of a share as of May 14, 2023.
F2 The Options have been issued from the Company's 2022 Equity Incentive Plan, that was approved by the Members of the Board of Directors on May 14, 2023.
F3 The Options will vest and become exercisable with respect to 40% of the shares starting May 14, 2023, with one forty-eighth (1/48th) of the shares vesting each calendar month thereafter on the same day of the month as the first vesting date. The remaining 60% of the shares will vest and become exercisable once HeartBeam, Inc. receives FDA Clearance for marketing of HeartBeam?s synthesized 12-Lead product obtained by signal synthesis from the recorded xyz signals.